Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Transaction Overview: Achilles Therapeutics has transferred its commercial license for data and samples from the TRACERx lung cancer study and its Material Acquisition Platform to AstraZeneca for $12 million, marking the conclusion of a strategic review by Achilles.
Future Plans: Following the transaction, Achilles Therapeutics plans to implement further organizational changes, including reducing employee headcount and Board size, while ensuring compliance with Nasdaq and SEC requirements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
